For adults with Chronic Idiopathic
Constipation (CIC)

Once-daily dosing.
Anytime with or without food.

Motegrity is a selective serotonin type 4 (5-HT4) receptor agonist.

Actor Portrayal

Motegrity (prucalopride) Dosing and Administration

Offers simple dosing to work with your patients’ schedules.1

Dosing icon

Once-daily dosing

Wrist watch

Any time of the day

Fork, spoon and knife

With or without food

It is important for patients to understand that Motegrity must be taken once daily as prescribed.1

Interested in receiving samples of Motegrity?

Your patients can benefit from a trial. Order a 7-day sample to get started.


Two dosage strengths

2 mg dose

2 mg

  • Recommended once daily adult Chronic Idiopathic Constipation (CIC) dosage1

1 mg dose

1 mg

  • Recommended once daily dosage for patients with Chronic Idiopathic Constipation (CIC) with severe renal impairment (creatinine clearance <30 mL‍/‍min)1
  • Avoid Motegrity in patients with end-stage renal disease requiring dialysis1

Motegrity® (prucalopride) bottle

Advise patients to:

  • Store Motegrity at 68°F to 77°F; with excursions permitted between 59°F to 86°F1
  • Store Motegrity in the original container to protect from moisture1
Bottle icon

Request Samples

Interested in receiving
samples of Motegrity?

Request samples
Map icon

Formulary Coverage

Wondering which plans in your area cover Motegrity? See our patient access coverage tool to find out more.

Patient access coverage tool


Expand Collapse

Please expand for Indication and Important Safety Information.


  • Hypersensitivity to Motegrity. Reactions including dyspnea, rash, pruritus, urticaria, and facial edema have been observed
  • Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract such as Crohn's disease, ulcerative colitis, and toxic megacolon/megarectum

Warnings and Precautions

Suicidal Ideation and Behavior: In clinical trials, suicides, suicide attempts and suicidal ideation have been reported. Postmarketing cases of suicidal ideation and behavior as well as self-injurious ideation and new onset or worsening of depression have been reported within the first few weeks of starting Motegrity. A causal association between treatment with Motegrity and an increased risk of suicidal ideation and behavior has not been established. Monitor patients for new onset or worsening of depression and emergence of suicidal thoughts and behavior. Instruct patients to discontinue Motegrity immediately and contact their healthcare provider if they experience any of these symptoms.

Adverse Reactions

Most common adverse reactions (≥2%) are headache, abdominal pain, nausea, diarrhea, abdominal distension, dizziness, vomiting, flatulence, and fatigue.

Use in Specific Populations

  • Lactation: Motegrity is present in breast milk. Consider risks and benefits of breastfeeding
  • Pediatric: Safety and effectiveness in pediatric patients have not been established
  • Renal Impairment: A decreased dosage is recommended in patients with severe renal impairment. Avoid Motegrity in patients with end-stage renal disease requiring dialysis


Motegrity® (prucalopride) is a serotonin-4 (5-HT4) receptor agonist indicated for the treatment of chronic idiopathic constipation (CIC) in adults.

Please click here for full Prescribing Information.


1. Motegrity (prucalopride) Prescribing Information. Lexington, MA: Takeda Pharmaceuticals America, Inc.